Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Life Science Research Center, University of South China, Hengyang, China.
Mol Med. 2010 Sep-Oct;16(9-10):438-49. doi: 10.2119/molmed.2010.00004. Epub 2010 May 12.
Atherosclerosis is characterized by a chronic inflammatory condition that involves numerous cellular and molecular inflammatory components. A wide array of inflammatory mediators, such as cytokines and proteins produced by macrophages and other cells, play a critical role in the development and progression of the disease. ATP-binding membrane cassette transporter A1 (ABCA1) is crucial for cellular cholesterol efflux and reverse cholesterol transport (RCT) and is also identified as an important target in antiatherosclerosis treatment. Evidence from several recent studies indicates that inflammation, along with other atherogenic-related mediators, plays distinct regulating roles in ABCA1 expression. Proatherogenic cytokines such as interferon (IFN)-γ and interleukin (IL)-1β have been shown to inhibit the expression of ABCA1, while antiatherogenic cytokines, including IL-10 and transforming growth factor (TGF)-β1, have been shown to promote the expression of ABCA1. Moreover, some cytokines such as tumor necrosis factor (TNF)-α seem to regulate ABCA1 expression in species-specific and dose-dependent manners. Inflammatory proteins such as C-reactive protein (CRP) and cyclooxygenase (COX)-2 are likely to inhibit ABCA1 expression during inflammation, and inflammation induced by lipopolysaccharide (LPS) was also found to block the expression of ABCA1. Interestingly, recent experiments revealed ABCA1 can function as an antiinflammatory receptor to suppress the expression of inflammatory factors, suggesting that ABCA1 may be the molecular basis for the interaction between inflammation and RCT. This review aims to summarize recent findings on the role of inflammatory cytokines, inflammatory proteins, inflammatory lipids, and the endotoxin-mediated inflammatory process in expression of ABCA1. Also covered is the current understanding of the function of ABCA1 in modulating the immune response and inflammation through its direct and indirect antiinflammatory mechanisms including lipid transport, high-density lipoprotein (HDL) formation and apoptosis.
动脉粥样硬化的特征是一种慢性炎症状态,涉及多种细胞和分子炎症成分。大量炎症介质,如巨噬细胞和其他细胞产生的细胞因子和蛋白质,在疾病的发展和进展中起着关键作用。三磷酸腺苷结合盒转运体 A1(ABCA1)对于细胞胆固醇外排和胆固醇逆向转运(RCT)至关重要,并且也被确定为抗动脉粥样硬化治疗的重要靶点。最近的几项研究证据表明,炎症以及其他与动脉粥样硬化相关的介质,在 ABCA1 表达中发挥着独特的调节作用。促动脉粥样硬化细胞因子,如干扰素(IFN)-γ和白细胞介素(IL)-1β已被证明抑制 ABCA1 的表达,而抗动脉粥样硬化细胞因子,包括 IL-10 和转化生长因子(TGF)-β1,已被证明促进 ABCA1 的表达。此外,一些细胞因子,如肿瘤坏死因子(TNF)-α,似乎以物种特异性和剂量依赖性的方式调节 ABCA1 的表达。炎症蛋白,如 C 反应蛋白(CRP)和环氧化酶(COX)-2,在炎症期间可能抑制 ABCA1 的表达,并且发现脂多糖(LPS)引起的炎症也会阻止 ABCA1 的表达。有趣的是,最近的实验揭示 ABCA1 可以作为一种抗炎受体发挥作用,抑制炎症因子的表达,这表明 ABCA1 可能是炎症与 RCT 相互作用的分子基础。本综述旨在总结炎症细胞因子、炎症蛋白、炎症脂质和内毒素介导的炎症过程在 ABCA1 表达中的作用的最新发现。还涵盖了目前对 ABCA1 通过其直接和间接的抗炎机制,包括脂质转运、高密度脂蛋白(HDL)形成和细胞凋亡,调节免疫反应和炎症的功能的理解。